At the 23rd annual dbAccess Global Consumer Conference, Brian McNamara, CEO of Haleon plc, reflected on the company's journey since its separation from GlaxoSmithKline (GSK) in July 2022. He highlighted that the initial phase involved ensuring business continuity and delivering on growth commitments while managing significant financial challenges, including reducing leverage from 4x to approximately 2.5x. McNamara noted that the company successfully eliminated a 45% overhang from its previous owners, Pfizer and GSK, which was crucial for its independence. Moving forward, he emphasized the importance of building a strong leadership team capable of realizing Haleon's full potential. This restructuring included key hires, such as Namrata Patel as head of supply chain, to enhance operational efficiency. McNamara's strategic focus aims to position Haleon for sustainable growth in the consumer health sector, reflecting a commitment to innovation and market responsiveness.